ABL Bio Inc. (KOSDAQ: 298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
26,400
-950 (-3.47%)
Dec 20, 2024, 9:00 AM KST
25.71%
Market Cap 1.27T
Revenue (ttm) 32.32B
Net Income (ttm) -49.04B
Shares Out 48.28M
EPS (ttm) -1,022.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 691,714
Open 27,100
Previous Close 27,350
Day's Range 26,400 - 27,450
52-Week Range 18,960 - 43,300
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Mar 14, 2025

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.